Add time:08/24/2019         Source:sciencedirect.com

SummaryPharmacological strategies have been employed to manipulate the response to atriopeptin (AP-28; ANF 99–126) in rats. These approaches include: heparin infusion which blocks the natriuresis-diuresis produced by exogenous AP infusion or by acute volume expansion; and autoimmune rats with endogenous antibody that blocks the natriuresis-diuresis produced by administration of exogenous AP or by acute volume expansion in anesthetized rats. Administration of the pressor analog 1-deamino-arg8-vasopressin (dAVP) to rats produces an elevation in systemic and right atrial blood pressure and markedly increases atriopeptin blood levels. The dAVP also produces a delayed natriuresis-diuresis which is effectively blunted in the autoimmune or heparin treated rats. The above approaches provide tools, in the absence of a specific receptor antagonist, with which to validate the intrinsic involvement of AP in physiological, pharmacological, or pathophysiological events.

We also recommend Trading Suppliers and Manufacturers of atriopeptin analog I (cas 117038-68-3). Pls Click Website Link as below: cas 117038-68-3 suppliers